124
Participants
Start Date
January 17, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
HX009+IN10018
"The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily."
RECRUITING
Peking University Cancer Hospital, Beijing
Lead Sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
INDUSTRY